C-EDGE.TN Study: Grazoprevir/Elbasvir in Genotype 1, 4, or 6 - Treatment for HCV Infection
The C-EDGE.TN Study evaluated the efficacy of grazoprevir/elbasvir treatment in patients with HCV infection, specifically genotype 1, 4, or 6. The study included 316 patients and aimed to achieve SVR12 rates superior to historical standards. The treatment was well-tolerated, with high SVR12 rates ac
0 views • 9 slides
Study on Grazoprevir and Elbasvir in Genotype 1 with Child-Pugh B Cirrhosis
The C-SALT study evaluated the efficacy of grazoprevir and elbasvir in patients with genotype 1 chronic HCV infection and Child-Pugh B cirrhosis. The primary endpoint was achieving sustained virologic response at 12 weeks. The study included treatment-naive and pre-treated patients with IFN-based re
0 views • 7 slides